Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CVS Caremark Launches Research Partnership To Improve Rx Adherence

Executive Summary

CVS Caremark is working with academic leaders from Carnegie Mellon University, Dartmouth College's Tuck School of Business, and the University of Pennsylvania's Medical School and the Wharton School of Business in an effort to help boost medication adherence for those suffering from chronic conditions

You may also be interested in...



Health IT Holds Potential To Improve Medication Adherence – CVS Caremark

Results from a recent study show that the use of health information technology holds the potential to improve medication adherence, but more research needs to be completed to determine what benefits technology can deliver in that area.

Health IT Holds Potential To Improve Medication Adherence – CVS Caremark

Results from a recent study show that the use of health information technology holds the potential to improve medication adherence, but more research needs to be completed to determine what benefits technology can deliver in that area.

CVS Caremark Sees Growth In Generic Drug Switches With Co-pay Waivers

CVS Caremark, working with State Farm Insurance plan members, found that offering a waiver of generic drug co-payments led to more switches to generics from their brand equivalents and that plan members were more likely to remain on the generic drug after the switch was made

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel